MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials

Neoplasia

Volumn 4, Issue 6, 2002, Pages 480-485

  Koutcher, Jason A ^a   Hu, Xiaoyi ^a   Xu, Su ^a   Gade, Terence P F ^a   Leeds, Norman ^b   Zhou, Xiaohong Joe ^b   Zagzag, David ^c   Holland, Eric C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Brain tumor; Glioblastoma; MRI; Oligodendrogliomas; Screening

Indexed keywords

GADOLINIUM PENTETATE; PROTEIN KINASE B; RAS PROTEIN; DIAGNOSTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CANCER DIAGNOSIS; CANCER GRADING; CANCER SCREENING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; GLIOMA; HISTOPATHOLOGY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; ANIMAL; BRAIN TUMOR; DISEASE MODEL; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; RADIOGRAPHY; RETROVIRUS; TRANSGENIC MOUSE;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GADOLINIUM DTPA; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROVIRIDAE;

EID: 0036857463     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900269     Document Type: Article

References (31)

1. Graif M, Bydder GM, Steiner RE, Niendorf P, Thomas DG, and Young IR (1985). Contrast-enhanced MR imaging of malignant brain tumors. Am J Neuroradiol 6, 855-62.
2. Roberts HC, Roberts TP, Brasch RC, and Dillon WP (2000). Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: Correlation with histologic grade. Am J Neuroradiol 21, 891-99.
3. Provenzale JM, Wang GR, Brenner T, Petrella JR, and Sorenson AG (2002). Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging. Am J Roentgenol 178, 711-16.
4. Blankenberg F, Conley FK, Sayre J, and Enzmann D (1991). MR imaging in an experimental model of brain tumor immunotherapy. Am J Neuroradiol 12, 543-48.
5. Chenevert TL, McKeever PE, and Ross BD (1997). Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging (1997). Clin Cancer Res 3, 1457-66.
6. Kim B, Chenevert TL, and Ross BD (1995). Growth kinetics and treatment response of the intracerebral rat 9 L brain tumor model: A quantitative in vivo study using magnetic resonance imaging. Clin Cancer Res 1, 643-50.
7. Kish PE, Blaivas M, Strawderman M, Muraszko KM, Ross DA, Ross BD, and McMahon G (2001). Magnetic resonance imaging of ethylnitrosourea-induced rat gliomas: A model for experimental therapeutics of low-grade gliomas. J Neuro-Oncol 53, 243-57.
8. Sherburn EW, Wanebo JE, Kim P, Song SK, Chicoine MR, and Woolsey TA (1999). Gliomas in rodent whisker barrel cortex: A new tumor model. J Neurosurg 91, 814-21.
9. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, and Ross BD (2000). Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92, 2029-36.
10. Stegman LD, Rehemtulla A, Hamstra DA, Rice DJ, Jonas SJ, Stout KL, Chenevert TL, and Ross BD (2000). Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther 7, 1005-10.
11. Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioglu O, Raghunand N, Ronen SM, Ross BD, and Swartz HM (2000). Applications of magnetic resonance in model systems: Cancer therapeutics. Neoplasia 2, 152-65.
12. Kaplan O, Firon M, Vivi A, Navon G, and Tsarfaty I (2000). HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. Neoplasia 2, 365-77.
13. Fleige G, Nolte C, Synowitz M, Seeberger F, Kettenmann H, and Zimmer C (2001). Magnetic labeling of activated microglia in experimental gliomas. Neoplasia 3, 489-99.
14. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, and Solaiyappan M (2001). Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 3, 143-53.
15. Pilatus U, Ackerstaff E, Artemov D, Mori N, Gillies RJ, and Bhujwalla ZM (2000). Imaging prostate cancer invasion with multi-nuclear magnetic resonance methods: The Metabolic Boyden Chamber. Neoplasia 2, 273-79.
16. Fujimoto JG, Pitris C, Boppart SA, and Brezinski ME (2000). Optical coherence tomography: An emerging technology for biomedical imaging and optical biopsy. Neoplasia 2, 9-25.
17. Vajkoczy P, Ullrich A, and Menger MD (2000). Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation. Neoplasia 2, 53-61.
18. Ramanujam N (2000). Fluorescence spectroscopy of neoplastic and non-neoplastic tissues. Neoplasia 2, 89-117.
19. Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, and Contag CH (1999). Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1, 303-10.
20. Contag CH, Jenkins D, Contag PR, and Negrin RS (2000). Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia 2, 41-52.
21. Paulus MJ, Gleason SS, Kennel SJ, Hunsicker PR, and Johnson DK (2000). High resolution X-ray computed tomography: An emerging tool for small animal cancer research. Neoplasia 2, 62-70.
22. Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, Finn R, Akhurst T, Larson S, Blasberg R, Sadelain M, and Tjuvajev JG (2001). Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia 3, 480-88.
23. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, Phelps ME, Larson SM, Balatoni J, Finn R, Sadelain M, Tjuvajev J, and Blasberg R (2000). Imaging transgene expression with radionuclide imaging technologies. Neoplasia 2, 118-38.
24. Gambhir SS, Barrio JR, Phelps ME, Iyer M, Namavari M, Satyamurthy N, Wu L, Green LA, Bauer E, MacLaren DC, Nguyen K, Berk AJ, Cherry SR, and Herschman HR (1999). Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci USA 96, 2333-38.
25. Mankoff DA, Dehdashti F, and Shields AF (2000). Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2, 71-88.
26. Fisher GH, Orsulic S, Holland EC, Hively WP, Li Y, Lewis BC, Williams BO, and Varmus HE (1999). Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 38, 5253-60.
27. Holland EC, Hively W, DePinho R, and Varmus H (1998). A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12, 3675-85.
28. Holland EC, and Varmus H (1998). Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 95, 1218-23.
29. Dai C, Celestino J, Okada Y, Louis DN, Fuller GN, and Holland EC (2001). PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15, 1913-25.
30. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, and Fuller GN (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25, 55-57.
31. Holland EC (2001). Gliomagenesis: Genetic alterations and mouse models. Nat Rev Genet 2, 120-29.